cagrilintide latest news CagriSema in Adults With or Without Diabetes – REDEFINE 1 & 2 • 💊 2.4 mg + Semaglutide 2.4 mg once weekly • 📉 –20.4% weight loss (non-diabetic) & –13.7% (T2D) Three new phase 3 REIMAGINE

Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema (cagrilintide + semaglutide) in type 2 diabetes. REIMAGINE 1 Studied people with early type 2 diabetes Trial Scorecard: REDEFINE 1 and 2 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Updates in Medicine REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio Phase 3a RCT in 1206 adults with T2D (BMI 27, HbA1c 710%) Instagram

SKU: 37079280524 · From centoria.fr